An interventional study of Lifestyle modifications and Pancreatic enzyme replacement therapy (PERT) and glycemic control therapy in Painless Chronic Pancreatitis, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Changhai Hospital · Not applicable, Interventional, and Treatment
Chronic pancreatitis (CP) is caused by factors such as genetics and the environment, leading to the destruction of pancreatic tissue, infiltration of inflammatory cells, and progressive fibrosis of the pancreas. As the disease progresses, pancreatic tissue is damaged, resulting in impaired endocrine and exocrine functions, manifesting as symptoms like steatorrhea and diabetes. Pain associated with chronic pancreatitis (PACP) is the most common symptom in CP patients. Approximately 75% of patients initially present with abdominal pain, and previous studies have shown that PACP can occur in 85-97% of CP patients. However, there is a type of pancreatitis where patients do not experience abdominal pain and typically seek medical attention due to routine check-ups or symptoms of pancreatic endocrine and exocrine dysfunction; this particular type of pancreatitis is known as painless CP. A meta-analysis showed that painless CP accounts for about 12% of all CP patients.
In patients with CP, continuous pancreatic damage leads to the destruction of pancreatic tissue, subsequently causing insufficiency in both exocrine and endocrine functions. "Painless" does not equate to "harmless"; patients with painless CP often present with severe symptoms of pancreatic exocrine and endocrine dysfunction at the time of diagnosis. These findings underscore the importance of early identification and active management of patients with painless CP.
Whether active endoscopic intervention is needed for painless CP remains a matter of debate. The European Society of Gastrointestinal Endoscopy (ESGE) suggests endoscopic therapy and/or extracorporeal shockwave lithotripsy (ESWL) as the first-line therapy for painful uncomplicated chronic pancreatitis (CP) with an obstructed main pancreatic duct (MPD) in the head/ body of the pancreas; however, due to the unclear potential benefits (preservation of pancreatic function) of endoscopic and/or ESWL treatment for painless CP, it is not recommended for patients without pain, although the evidence is of low quality.
Although there is currently no consensus on whether endoscopic treatment can protect the pancreatic function of patients with painless chronic pancreatitis, preliminary evidence suggests that endoscopic treatment may have a positive impact on pancreatic atrophy and dysfunction in patients with painless CP. In a retrospective study by Ikeura et al., which included 268 patients with CP and painless pancreatic duct stones, it was found that endoscopic treatment and complete clearance of stones in patients with painless pancreatic duct stones helped maintain the volume of the pancreatic parenchyma.
Although preliminary research suggests that endoscopic treatment may protect pancreatic function in patients with painless CP, it could also trigger pain. A study by Ikeura et al. found that painless CP patients who underwent endoscopic treatment but did not have complete clearance of pancreatic duct stones were at a significantly higher risk of developing pain. This indicates that incomplete endoscopic treatment might lead patients from a painless state to one of pain. However, a study by Amodio et al. suggests that the likelihood of painless CP patients experiencing pain in the short term is low, implying that conservative treatment might be more appropriate.
Current research on the clinical characteristics of painless CP and its response to treatment is relatively limited, necessitating further clinical studies to clarify the impact of ERCP and/or ESWL on these patients. We plan to conduct a randomized controlled trial to assess whether these minimally invasive interventions can improve clinical outcomes for patients with painless CP
This is a randomized controlled trial comparing endotherapy combined with extracorporeal shock-wave lithotripsy (ESWL) versus conservative management in participants with painless chronic pancreatitis. A total of 126 eligible participants will be randomized 1:1 to either the endotherapy-plus-ESWL arm or the conservative-treatment arm. The primary endpoint will be evaluated at 1-year follow-up. And participants will enter long-term follow-up up to 10 years post-randomization.
264 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
This study's planned enrollment of 126 is above the median of 45 across 143 interventional studies indexed under Pancreatitis, Chronic.
Browse Pancreatitis, Chronic studies →Changhai Hospital is the lead sponsor of 355 studies on the registry; 137 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will undergo a comprehensive treatment approach that includes lifestyle modifications, pharmacological interventions, and procedural therapies including ERCP and/or extracorporeal shock-wave lithotripsy (ESWL). 1. For main pancreatic duct strictures persisting after initial single plastic stent placement for one year, multiple stents or surgery may be considered. 2. During follow-up, if pancreatic pain or acute pancreatitis occurs, a multidisciplinary team will assess attack frequency and clinical severity and decide whether repeat minimally invasive therapy is indicated. 3. If CP-related complications (including pancreatic pseudocyst, biliary stricture, pancreatic portal hypertension, pancreatic fistula, etc.) occur and meet intervention indications, endoscopic or surgical intervention will be performed in accordance with clinical guidelines 4. Surgery will be performed for mass-forming chronic pancreatitis with inconclusive diagnosis.
Behavioral: Lifestyle modifications · Drug: Pancreatic enzyme replacement therapy (PERT) and glycemic control therapy · Procedure: Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or Extracorporeal Shockwave Lithotripsy (ESWL)
This arm includes participants who will receive standard conservative management for painless chronic pancreatitis. 1. The treatment regimen comprises lifestyle modification and medications to manage symptoms of pancreatic exocrine and endocrine insufficiency, such as pancreatic enzyme supplements and medications for diabetes management (e.g., oral hypoglycemics or insulin). 2. During follow-up, if pancreatic pain or acute pancreatitis occurs, a multidisciplinary team will assess attack frequency and clinical severity and decide whether minimally invasive therapy is indicated. 3. If CP-related complications (including pancreatic pseudocyst, biliary stricture, pancreatic portal hypertension, pancreatic fistula, etc.) occur and meet intervention indications, endoscopic or surgical intervention will be performed in accordance with clinical guidelines 4. Surgery will be performed for mass-forming chronic pancreatitis with inconclusive diagnosis.
Behavioral: Lifestyle modifications · Drug: Pancreatic enzyme replacement therapy (PERT) and glycemic control therapy
Lifestyle modifications primarily include quitting smoking and alcohol consumption, as well as engaging in physical exercise.
This intervention involves the use of medications to control the pancreatic exocrine and endocrine dysfunction caused by chronic pancreatitis. 1. Pancreatic enzyme therapy: Patients will use pancreatic enzymes (pancreatin enteric-coated capsules or oryz-aspergillus enzyme and pancreatin tablets) to control the symptoms of exocrine pancreatic insufficiency. 2. Diabetes treatment: Patients with diabetes will also use antidiabetic medications (such as oral hypoglycemic drugs or insulin, depending on glycemic control needs).
This intervention involves the application of endoscopic retrograde cholangiopancreatography (ERCP) and/or extracorporeal shockwave lithotripsy (ESWL). The procedures are tailored to the individual patient's condition, which may include sphincterotomy, dilation of pancreatic duct strictures, stone extraction, stent placement and other interventions as indicated. ESWL may be used prior to ERCP to fragment pancreatic duct stones, facilitating their removal.
Acute Pancreatitis Incidence
The incidence of acute pancreatitis assessed by Revised Atlanta Classification over a 12-month period following randomization.
Time frame: 12 months
Severity of Acute Pancreatitis
The severity of acute pancreatitis episodes that occur within 12 months post randomization. Severity will be graded according to the Atlanta Classification criteria, which categorizes pancreatitis into mild, moderate, and severe based on clinical and imaging findings.
Time frame: 12 months
Incidence and Severity of Pancreatic Pain
The incidence and severity of pancreatic pain over a 12-month period. Pain severity will be measured using the Visual Analogue Scale (VAS), where patients rate their pain on a scale from 0 (no pain) to 10 (worst possible pain).
Time frame: 12 months
Number of Acute Pancreatitis Episodes
Time frame: 12 months
Number of pancreatic pain episodes
Time frame: 12 months
Fecal Elastase-1 Level
This outcome assesses pancreatic exocrine function by measuring fecal elastase-1 (FE-1) levels
Time frame: 12 months
Glycosylated Hemoglobin Level
This outcome measure evaluates the percentage of hemoglobin that is glycosylated, reflecting the average blood glucose levels over the past 2 to 3 months. It is a key indicator of long-term glycose level in patients.
Time frame: 12 months
Fasting Blood Glucose Level
This outcome measure assesses the level of glucose in the blood after an overnight fast. Fasting glucose is a standard test for diagnosing diabetes and monitoring diabetes control. It provides a snapshot of the body's ability to manage glucose without the influence of food.
Time frame: 12 months
Fasting C-Peptide Concentration
This outcome measure determines the concentration of C-peptide in the blood during a fasting state. C-peptide is a byproduct of insulin production and provides an index of endogenous insulin secretion. It is useful for assessing insulin production capacity.
Time frame: 12 months
Fasting Insulin Concentration
Time frame: 12 months
C-peptide Area Under the Curve (AUC) Post MMTT
This outcome measures the total exposure to C-peptide over the first 2 hours following a mixed meal tolerance test (MMTT). The AUC is calculated using Riemann sums based on the midpoint of each interval (0, 30, 60, 90, and 120 minutes). This metric is crucial for assessing the overall insulin secretion capacity of the islets.
Time frame: 12 months
Glucose Area Under the Curve (AUC) Post MMTT
This outcome assesses the total glucose exposure over the first 2 hours following a Mixed Meal Tolerance Test (MMTT). The AUC is determined using Riemann sums based on the midpoint of each interval (0, 30, 60, 90, and 120 minutes). This metric is essential for evaluating the body's glucose handling ability and the effectiveness of glucose control.
Time frame: 12 months
Insulin Area Under the Curve (AUC) Post MMTT
This outcome measures the total insulin exposure over the first 2 hours following a Mixed Meal Tolerance Test (MMTT). The AUC is calculated using Riemann sums based on the midpoint of each interval (0, 30, 60, 90, and 120 minutes). This metric is vital for assessing the overall insulin secretion response to a meal and the effectiveness of insulin production.
Time frame: 12 months
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
The HOMA-IR is calculated from fasting glucose and fasting insulin levels obtained during the MMTT. It provides an estimate of insulin resistance and is calculated using the formula: HOMA-IR= (fasting glucose × fasting insulin)/405. This index is crucial for understanding the body's insulin sensitivity.
Time frame: 12 months
Homeostatic Model Assessment of β-cell Function (HOMA-b)
HOMA-b is determined by the formula HOMA b = (fasting insulin × 360)/(fasting glucose - 63) to assess insulin secretion. It provides an estimate of the β-cell function in response to fasting glucose levels.
Time frame: 12 months
Insulinogenic Index Post MMTT
The insulinogenic index is a measure of the early insulin response to a glucose challenge, calculated as (Δinsulin30-0min / Δglucose30-0min). It reflects the capacity of the β-cells to secrete insulin in response to a rise in blood glucose levels.
Time frame: 12 months
C-peptide Secretion Index Post MMTT
This index is calculated by replacing insulin with C-peptide in the insulinogenic index formula, i.e., (ΔC-peptide30-0min / Δglucose30-0min). It serves as a measure of the early C-peptide response to a glucose challenge, providing information about the secretory capacity of the islets.
Time frame: 12 months
Disposition Index for C-peptide
The disposition index for C-peptide is calculated as (ΔC-peptide30-0min / Δglucose30-0min) × (1 / fasting C-peptide). It represents the ratio of insulin or C-peptide secretion to sensitivity and is an important indicator of the overall β-cell function and insulin sensitivity.
Time frame: 12 months
Rate of Pancreatic Exocrine Insufficiency
Derived outcome based on fecal elastase-1 measurement
Time frame: 12 months
Rate of Pancreatic Endocrine Insufficiency
Derived endocrine functional status based on fasting glucose, HbA1c and mixed-meal tolerance test.
Time frame: 12 months
Change of Pancreatic Exocrine and Endocrine Function Status From Baseline
Categorical change in pancreatic functional status relative to baseline: persistent insufficiency, new-onset insufficiency, resolution of pre-existing insufficiency, persistently normal pancreatic function.
Time frame: 12 months
Rate of Disease Progression
Proportion of participants with new-onset chronic-pancreatitis-related complications, including pancreatic pseudocysts, benign biliary strictures, pancreatic fistulas, pancreatic portal hypertension, and other related complications
Time frame: 12 months
Quality of Life Assessed by SF-36
This outcome evaluates the quality of life (QoL) of patients with painless chronic pancreatitis at two time points: at baseline (time of hospital admission) and at 12 months post-randomization. The assessment is conducted using the Short Form Health Survey (SF-36), a widely recognized and validated tool that measures health-related quality of life across eight dimensions: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The SF-36 provides a comprehensive overview of how the condition and treatment affect the patients' overall well-being and daily functioning.
Time frame: 12 months
Long-term Outcome Assessment
Reassessment of pre-specified primary and secondary outcome measures at 3, 5, and 10 years post-randomization, to evaluate the long-term effects of the two treatment strategies.
Time frame: 3, 5, and 10 years post-randomization
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.